Lung Diseases, Interstitial
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The serum KL-6 levels in patients with ILD were significantly positively correlated with the CT scores (r=0.539, P=0.000) and negatively correlated with DLCO (r=-0.513, P=0.000).
|
30007895 |
2020 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
Evaluation of the clinical performance of the HISCL-5000 analyzer in the detection of Krebs von den Lungen-6 antigen and its diagnostic value in interstitial lung disease.
|
31691368 |
2020 |
Lung Diseases, Interstitial
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In both treatment arms (n = 71 for CYC, n = 62 for MMF), a higher baseline KL-6 level predicted progression of ILD based on the course of FVC (P = 0.024 for CYC; P = 0.005 for MMF) and DLco (P < 0.001 for CYC; P = 0.004 for MMF) over 1 year.
|
31233287 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The serum KL-6 levels were significantly higher in patients with CADM-ILD (1339 ± 1329 U/mL) compared with DM-ILD (642.3 ± 498.4 U/mL) and healthy donors (162.4 ± 54.01 U/mL).
|
31301087 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
Serum KL-6 is a useful biomarker for assessing the disease activity of myositis-associated ILD.
|
30624752 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The baseline level of serum Krebs von den Lungen-6 (KL-6) and C-X-C motif chemokine 13 (CXCL13) were moderately or highly correlated with annual changes in forced vital capacity (FVC), carbon monoxide diffusing capacity (DLCO), total lung capacity (TLC), total interstitial lung disease (ILD) lesions, and the volume changes of reticular.
|
31740085 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The factors related to ILD deterioration were use of methotrexate (MTX) [odds ratio 12.75, 95% confidence interval (CI) 1.09-148.77], and change in Krebs von-den Lungen-6 (odds ratio 1.00, 95% CI 1.00-1.01), according to multivariate logistic regression analysis.
|
29798700 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CTD-ILD patients (n = 165) had elevated serum KL-6 levels compared to CTD patients without ILD (n = 384) (p < 0.001), and those findings were preserved after adjusting for age, sex, and CTD type.
|
30764869 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-18, Krebs von den Lungen-6, and anti-cyclic citrullinated peptide antibody titre and glucocorticoid doses were independently associated with the presence of ILD during multivariate logistic regression analysis.
|
30269670 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, there is converging evidence that C-reactive protein and pneumoproteins such as Krebs von den Lungen-6 and chemokine ligand 18 could serve as prognostic biomarkers in systemic sclerosis-associated interstitial lung disease.
|
31436584 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lower %FVC and higher serum KL-6 levels are predictive factors for poor outcome in patients with pSS-ILD.
|
31710871 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The median serum KL-6 level was 1450.5 U/mL (interquartile range (IQR) 742.9-2603.2) in the CTD with ILD group, 415.9 U/mL (IQR 233.4-748.4) in the CTD without ILD group, and 465.9 U/mL (IQR 273.6-1036) in the control group.
|
31784789 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
Baseline elevated serum KL-6 may predict deterioration of lung function of SSc-ILD patients with mild lung injury.
|
30592376 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study is the first to compare assay platforms and show correlations between KL-6 concentrations and HRCT or PFT results in Korean ILD patients.
|
30623616 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
High KL-6 and smoking histories might be predictive for ILD among patients with HNSCC.
|
30828911 |
2019 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
ILD and anti-topoisomerase 1 antibodies were independent factors associated with KL-6 in multivariate analysis.
|
29455320 |
2018 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the sensitivity of both TARC/CCL17 and KL-6 was almost equal, the mean concentration of serum KL-6 after the progression of interstitial lung disease was significantly higher than that before progression.
|
30174428 |
2018 |
Lung Diseases, Interstitial
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ILD severity/activity before treatment and variability of serum KL-6 and SP-D levels during treatment may be useful to predict therapeutic effects of IVCY on SSc-ILD.
|
30289572 |
2018 |
Lung Diseases, Interstitial
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that high fever, arthralgia, muscle weakness, and high serum Krebs von den Lungen-6 (KL-6) level were significantly associated with the presence of ILD (p < 0.05).
|
27588444 |
2017 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
Krebs von den Lungen-6 (KL-6), a mucinous sialylated sugar chain on human mucin-1 glycoprotein (MUC1), is a diagnostic marker for interstitial lung diseases.
|
28693233 |
2017 |
Lung Diseases, Interstitial
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, in the lungs of patients with interstitial lung disease, MUC1 is aberrantly expressed in hyperplastic alveolar type II epithelial (ATII) cells and alveolar macrophages (AM), and elevated levels of extracellular MUC1 are found in bronchoalveolar lavage (BAL) fluid and the serum of these patients.
|
28916165 |
2017 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study suggests that serum KL-6 can be a useful monitoring tool of SSc/MCTD-associated ILD activity.
|
28275485 |
2017 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients.
|
26077281 |
2017 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
KL-6, a human MUC1 mucin, is a sensitive biomarker for interstitial lung diseases including pulmonary alveolar proteinosis (PAP).
|
27108412 |
2016 |
Lung Diseases, Interstitial
|
0.100 |
Biomarker
|
group |
BEFREE |
Serum Krebs von den Lungen-6 (KL-6), which is classified as human mucin-1 (MUC1), is used as a marker of sarcoidosis and other interstitial lung diseases.
|
22650152 |
2012 |